Xenetic Biosciences, Inc. (XBIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenetic Biosciences, Inc. on October 29, 2024. The report addresses corporate governance changes regarding the Board of Directors ahead of the Company's 2024 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
On October 29, 2024, two members of the Board of Directors, James E. Callaway and Adam Logal, informed the Company of their intention not to stand for re-election at the upcoming 2024 Annual Meeting of Stockholders. The Company stated that neither director's decision was related to any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management expressed gratitude for the dedicated service of Dr. Callaway and Mr. Logal. The report was signed by James Parslow, who holds the titles of Interim Chief Executive Officer and Chief Financial Officer.
Key Facts for Investor Verification
- James E. Callaway and Adam Logal will not seek re-election to the Board of Directors.
- The departures are not attributed to any disagreement with the Company.
- James Parslow is currently serving as Interim CEO and CFO.
- Investors should verify the composition of the Board following the 2024 Annual Meeting of Stockholders.